INTERVENTION 1:	Intervention	0
Cohort A: KNp / KAC	Intervention	1
Participants received pembrolizumab (K) 200 mg on Cycle 1 Day 1 followed by pembrolizumab 200 mg in Cycles 2-5 on Day 1 (once every 3 weeks; Q3W) PLUS nab-paclitaxel (KNp) starting at 125 mg/m^2 in Cycles 2-5 on Days 1, 8 and 15 (once each week; QW). This was followed by pembrolizumab (K) 200 mg in Cycles 6-9 on Day 1 (Q3W) PLUS doxorubicin (A) 60 mg/m^2 in Cycles 6-9 on Day 1 (Q3W) PLUS cyclophosphamide (C) 600 mg/m^2 in Cycles 6-9 on Day 1 (Q3W). All treatments were administered via intravenous (IV) infusion except for doxorubicin (A), which was administered via IV injection. Each cycle was 21 days.	Intervention	2
day	UO:0000033	58-61
day	UO:0000033	114-117
day	UO:0000033	212-215
day	UO:0000033	314-317
day	UO:0000033	374-377
day	UO:0000033	440-443
day	UO:0000033	603-606
week	UO:0000034	134-138
week	UO:0000034	240-244
doxorubicin	CHEBI:28748,BAO:0000639	331-342
doxorubicin	CHEBI:28748,BAO:0000639	527-538
cyclophosphamide	CHEBI:4026	391-407
INTERVENTION 2:	Intervention	3
Cohort B: KNpCb (Regimen 1) / KAC	Intervention	4
Participants first received KNpCb Regimen 1 which consisted of: pembrolizumab (K) 200 mg on Cycle 1 Day 1 PLUS nab-paclitaxel (KNp) starting at 100 mg/m^2 in Cycles 2-5 on Days 1, 8 and 15 (QW) PLUS carboplatin (Cb) starting at Area Under the Curve (AUC) 6 in Cycles 2-5 on Day 1 (Q3W). This was followed by pembrolizumab (K) 200 mg in Cycles 6-9 on Day 1 (Q3W) PLUS doxorubicin (A) 60 mg/m^2 in Cycles 6-9 on Day 1 (Q3W) PLUS cyclophosphamide (C) 600 mg/m^2 in Cycles 6-9 on Day 1 (Q3W). All treatments were administered via IV infusion except for doxorubicin (A), which was administered via IV injection. Each cycle was 21 days.	Intervention	5
day	UO:0000033	100-103
day	UO:0000033	172-175
day	UO:0000033	274-277
day	UO:0000033	350-353
day	UO:0000033	410-413
day	UO:0000033	476-479
day	UO:0000033	625-628
carboplatin	CHEBI:31355	199-210
area	PATO:0001323	228-232
auc	BAO:0002120	250-253
doxorubicin	CHEBI:28748,BAO:0000639	367-378
doxorubicin	CHEBI:28748,BAO:0000639	549-560
cyclophosphamide	CHEBI:4026	427-443
Inclusion Criteria:	Eligibility	0
Has previously untreated, locally advanced TNBC.	Eligibility	1
Is able to provide 2 core needle biopsies from the primary tumor at screening to the central laboratory and agrees to have a core needle biopsy after single dose pembrolizumab treatment if tumor biopsy is feasible as judged by the investigator.	Eligibility	2
central	HP:0030645	85-92
Has Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1.	Eligibility	3
group	CHEBI:24433	33-38
Has adequate organ function.	Eligibility	4
organ	UBERON:0000062	13-18
function	BAO:0003117,BFO:0000034	19-27
Females of childbearing potential must be willing to use adequate contraception for the course of the study through 12 months after the last dose of study drug for participants receiving cyclophosphamide and through 6 months after the last dose of study drug for participants who do not receive cyclophosphamide.	Eligibility	5
drug	CHEBI:23888	155-159
drug	CHEBI:23888	254-258
cyclophosphamide	CHEBI:4026	187-203
cyclophosphamide	CHEBI:4026	295-311
Exclusion Criteria:	Eligibility	6
Has evidence of metastatic breast cancer, concurrent bilateral invasive breast cancer, or inflammatory breast cancer.	Eligibility	7
breast cancer	DOID:1612	27-40
breast cancer	DOID:1612	72-85
breast cancer	DOID:1612	103-116
bilateral	HP:0012832	53-62
Has another malignancy within the last 5 years. Exceptions include basal cell carcinoma of the skin, squamous cell carcinoma of the skin that has undergone potentially curative surgery, or in situ cervical cancer.	Eligibility	8
basal cell carcinoma	HP:0002671,DOID:2513	67-87
squamous cell carcinoma of the skin	HP:0006739	101-136
surgery	OAE:0000067	177-184
cervical cancer	DOID:4362	197-212
Has received prior chemotherapy, targeted therapy, radiation therapy, immunotherapy that targets immune checkpoints, co-stimulatory or co-inhibitory pathways for T cell receptors within the past 12 months.	Eligibility	9
t	CHEBI:36371,BAO:0001260	24-25
t	CHEBI:36371,BAO:0001260	33-34
t	CHEBI:36371,BAO:0001260	38-39
t	CHEBI:36371,BAO:0001260	42-43
t	CHEBI:36371,BAO:0001260	56-57
t	CHEBI:36371,BAO:0001260	61-62
t	CHEBI:36371,BAO:0001260	76-77
t	CHEBI:36371,BAO:0001260	84-85
t	CHEBI:36371,BAO:0001260	87-88
t	CHEBI:36371,BAO:0001260	89-90
t	CHEBI:36371,BAO:0001260	94-95
t	CHEBI:36371,BAO:0001260	113-114
t	CHEBI:36371,BAO:0001260	121-122
t	CHEBI:36371,BAO:0001260	127-128
t	CHEBI:36371,BAO:0001260	144-145
t	CHEBI:36371,BAO:0001260	151-152
t	CHEBI:36371,BAO:0001260	162-163
t	CHEBI:36371,BAO:0001260	174-175
t	CHEBI:36371,BAO:0001260	181-182
t	CHEBI:36371,BAO:0001260	186-187
t	CHEBI:36371,BAO:0001260	193-194
t	CHEBI:36371,BAO:0001260	201-202
Is currently participating and receiving study therapy, or has participated in a study of an investigational agent and received study therapy or used an investigational device within 4 weeks of the first dose of study drug.	Eligibility	10
drug	CHEBI:23888	218-222
Has received a live vaccine within 30 days of the first dose of study drug.	Eligibility	11
vaccine	VO:0000001	20-27
drug	CHEBI:23888	70-74
Has an active autoimmune disease that has required systemic treatment in past 2 years.	Eligibility	12
active	PATO:0002354	7-13
autoimmune disease	DOID:417	14-32
Has a diagnosis of immunodeficiency or is receiving systemic steroid therapy or any other form of immunosuppressive therapy within 7 days prior to the first dose of study drug.	Eligibility	13
immunodeficiency	HP:0002721	19-35
steroid	CHEBI:35341	61-68
drug	CHEBI:23888	171-175
Has a known history of Human Immunodeficiency Virus (HIV).	Eligibility	14
history	BFO:0000182	12-19
immunodeficiency	HP:0002721	29-45
virus	BAO:0000232	46-51
Has known active Hepatitis B or Hepatitis C.	Eligibility	15
active	PATO:0002354	10-16
hepatitis b	DOID:2043	17-28
hepatitis c	DOID:1883	32-43
Has evidence of current pneumonitis.	Eligibility	16
Has a history of non-infectious pneumonitis requiring treatment with steroids or a history of interstitial lung disease.	Eligibility	17
history	BFO:0000182	6-13
history	BFO:0000182	83-90
interstitial lung disease	DOID:3082	94-119
Has an active infection requiring systemic therapy.	Eligibility	18
active	PATO:0002354	7-13
Has significant cardiovascular disease, such as: History of myocardial infarction, acute coronary syndrome or coronary angioplasty/stenting/bypass grafting within the last 6 months; Congestive heart failure (CHF) New York Heart Association (NYHA) Class II-IV or history of CHF NYHA class III or IV	Eligibility	19
disease	DOID:4,OGMS:0000031	31-38
history	BFO:0000182	49-56
history	BFO:0000182	262-269
myocardial infarction	HP:0001658,DOID:5844	60-81
acute coronary syndrome	HP:0033678	83-106
congestive heart failure	HP:0001635,DOID:6000	182-206
heart	UBERON:0000948	193-198
heart	UBERON:0000948	222-227
Has known psychiatric or substance abuse disorders that would interfere with cooperation with the requirements of the study.	Eligibility	20
substance abuse	DOID:302	25-40
Is pregnant or breastfeeding, or expecting to conceive children within the projected duration of the study, starting with the screening visit through 12 months after the last dose of trial treatment for participants who have received cyclophosphamide, and for six months after the last dose of study medication for participants who have not.	Eligibility	21
duration	PATO:0001309	85-93
cyclophosphamide	CHEBI:4026	234-250
Has a known hypersensitivity to the components of the study drug or its analogs.	Eligibility	22
hypersensitivity	GO:0002524,DOID:1205	12-28
drug	CHEBI:23888	60-64
Outcome Measurement:	Results	0
Number of Participants With Dose Limiting Toxicities (DLTs) Graded Using National Cancer Institute Common Toxicity Criteria for Adverse Events Version 4.0 (NCI CTCAE v4.0)	Results	1
cancer	DOID:162	82-88
The following events, if considered to be study-treatment-related by the Investigator, were considered a DLT:	Results	2
Hematologic:	Results	3
Grade 4 neutropenia lasting 8 days;	Results	4
neutropenia	HP:0001875,DOID:1227	8-19
Febrile neutropenia Grade 3 or Grade 4; or	Results	5
neutropenia	HP:0001875,DOID:1227	8-19
Grade 4 thrombocytopenia requiring platelet transfusion, or Grade 3 thrombocytopenia with bleeding	Results	6
thrombocytopenia	HP:0001873,DOID:1588	8-24
thrombocytopenia	HP:0001873,DOID:1588	68-84
Non-hematologic:	Results	7
Grade 4 toxicity;	Results	8
Grade 3 symptomatic hepatic toxicities lasting >48 hours, or Grade 3 asymptomatic hepatic toxicities lasting 7 days; or	Results	9
Grade 3 non-hematologic, non-hepatic organ toxicity, with exceptions	Results	10
organ	UBERON:0000062	37-42
Other:	Results	11
Any treatment delays for 14 days due to unresolved toxicity;	Results	12
Grade 5 treatment-related adverse event (AE);	Results	13
adverse event	OAE:0000001	26-39
A dose reduction of study treatment during the DLT evaluation period.	Results	14
Time frame: Cycle 1 Day 1 through end of Cycle 3 and Cycle 6 Day 1 through end of Cycle 7 (Up to ~150 days from first dose of first combination regimen); Each cycle was 21 days.	Results	15
time	PATO:0000165	0-4
day	UO:0000033	20-23
day	UO:0000033	61-64
day	UO:0000033	102-105
day	UO:0000033	172-175
Results 1:	Results	16
Arm/Group Title: Cohort A: KNp / KAC	Results	17
Arm/Group Description: Participants received pembrolizumab (K) 200 mg on Cycle 1 Day 1 followed by pembrolizumab 200 mg in Cycles 2-5 on Day 1 (once every 3 weeks; Q3W) PLUS nab-paclitaxel (KNp) starting at 125 mg/m^2 in Cycles 2-5 on Days 1, 8 and 15 (once each week; QW). This was followed by pembrolizumab (K) 200 mg in Cycles 6-9 on Day 1 (Q3W) PLUS doxorubicin (A) 60 mg/m^2 in Cycles 6-9 on Day 1 (Q3W) PLUS cyclophosphamide (C) 600 mg/m^2 in Cycles 6-9 on Day 1 (Q3W). All treatments were administered via intravenous (IV) infusion except for doxorubicin (A), which was administered via IV injection. Each cycle was 21 days.	Results	18
day	UO:0000033	81-84
day	UO:0000033	137-140
day	UO:0000033	235-238
day	UO:0000033	337-340
day	UO:0000033	397-400
day	UO:0000033	463-466
day	UO:0000033	626-629
week	UO:0000034	157-161
week	UO:0000034	263-267
doxorubicin	CHEBI:28748,BAO:0000639	354-365
doxorubicin	CHEBI:28748,BAO:0000639	550-561
cyclophosphamide	CHEBI:4026	414-430
Overall Number of Participants Analyzed: 10	Results	19
Measure Type: Count of Participants	Results	20
Unit of Measure: Participants  2  20.0%	Results	21
Results 2:	Results	22
Arm/Group Title: Cohort B: KNpCb (Regimen 1) / KAC	Results	23
Arm/Group Description: Participants first received KNpCb Regimen 1 which consisted of: pembrolizumab (K) 200 mg on Cycle 1 Day 1 PLUS nab-paclitaxel (KNp) starting at 100 mg/m^2 in Cycles 2-5 on Days 1, 8 and 15 (QW) PLUS carboplatin (Cb) starting at Area Under the Curve (AUC) 6 in Cycles 2-5 on Day 1 (Q3W). This was followed by pembrolizumab (K) 200 mg in Cycles 6-9 on Day 1 (Q3W) PLUS doxorubicin (A) 60 mg/m^2 in Cycles 6-9 on Day 1 (Q3W) PLUS cyclophosphamide (C) 600 mg/m^2 in Cycles 6-9 on Day 1 (Q3W). All treatments were administered via IV infusion except for doxorubicin (A), which was administered via IV injection. Each cycle was 21 days.	Results	24
day	UO:0000033	123-126
day	UO:0000033	195-198
day	UO:0000033	297-300
day	UO:0000033	373-376
day	UO:0000033	433-436
day	UO:0000033	499-502
day	UO:0000033	648-651
carboplatin	CHEBI:31355	222-233
area	PATO:0001323	251-255
auc	BAO:0002120	273-276
doxorubicin	CHEBI:28748,BAO:0000639	390-401
doxorubicin	CHEBI:28748,BAO:0000639	572-583
cyclophosphamide	CHEBI:4026	450-466
Overall Number of Participants Analyzed: 10	Results	25
Measure Type: Count of Participants	Results	26
Unit of Measure: Participants  4  40.0%	Results	27
Adverse Events 1:	Adverse Events	0
Total: 5/10 (50.00%)	Adverse Events	1
Anaemia 0/10 (0.00%)	Adverse Events	2
Febrile neutropenia 1/10 (10.00%)	Adverse Events	3
neutropenia	HP:0001875,DOID:1227	8-19
Lymphadenitis 0/10 (0.00%)	Adverse Events	4
lymphadenitis	HP:0002840,DOID:1602	0-13
Neutropenia 0/10 (0.00%)	Adverse Events	5
neutropenia	HP:0001875,DOID:1227	0-11
Abdominal pain upper 0/10 (0.00%)	Adverse Events	6
abdominal pain	HP:0002027	0-14
Colitis 0/10 (0.00%)	Adverse Events	7
colitis	HP:0002583,DOID:0060180	0-7
Diarrhoea 0/10 (0.00%)	Adverse Events	8
Nausea 1/10 (10.00%)	Adverse Events	9
nausea	HP:0002018	0-6
Oesophagitis 0/10 (0.00%)	Adverse Events	10
Pyrexia 0/10 (0.00%)	Adverse Events	11
Autoimmune hepatitis 0/10 (0.00%)	Adverse Events	12
autoimmune hepatitis	DOID:2048	0-20
Influenza 0/10 (0.00%)	Adverse Events	13
influenza	DOID:8469	0-9
Adverse Events 2:	Adverse Events	14
Total: 4/10 (40.00%)	Adverse Events	15
Anaemia 0/10 (0.00%)	Adverse Events	16
Febrile neutropenia 2/10 (20.00%)	Adverse Events	17
neutropenia	HP:0001875,DOID:1227	8-19
Lymphadenitis 0/10 (0.00%)	Adverse Events	18
lymphadenitis	HP:0002840,DOID:1602	0-13
Neutropenia 1/10 (10.00%)	Adverse Events	19
neutropenia	HP:0001875,DOID:1227	0-11
Abdominal pain upper 0/10 (0.00%)	Adverse Events	20
abdominal pain	HP:0002027	0-14
Colitis 0/10 (0.00%)	Adverse Events	21
colitis	HP:0002583,DOID:0060180	0-7
Diarrhoea 0/10 (0.00%)	Adverse Events	22
Nausea 0/10 (0.00%)	Adverse Events	23
nausea	HP:0002018	0-6
Oesophagitis 0/10 (0.00%)	Adverse Events	24
Pyrexia 1/10 (10.00%)	Adverse Events	25
Autoimmune hepatitis 0/10 (0.00%)	Adverse Events	26
autoimmune hepatitis	DOID:2048	0-20
Influenza 0/10 (0.00%)	Adverse Events	27
influenza	DOID:8469	0-9
